SS-31
Also known as: Elamipretide
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto (Cornell) and clinically advanced by Stealth BioTherapeutics. It concentrates in the inner mitochondrial membrane by binding cardiolipin. In September 2025, the FDA granted accelerated approval to elamipretide (brand name FORZINITY) as the first therapy for Barth syndrome — the first FDA-approved mitochondria-targeted drug. It remains investigational for other indications.
Who's worth your money for SS-31
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 14 scored sellers
$320 · 50mg · 99.8% purity
Most tested
4 independent COAs on file
$250 · 50mg · 99.8% purity
Average price
$4.77/mg
Sellers
60
45-day trend
+7.8%
52 of 60 sellers have a current price· 21 stale hidden· 17 unverified hidden
Top Merit pick
🇺🇸 Peptide Partners99✓ verified at source · 23h ago
$6.40/mg +34.1% vs avg$320
50mg
- 🇺🇸 Reta One Labs95
✓ verified at source · 23h ago
$3.40/mg -28.8% vs avg$34.00
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 23h ago
$5.00/mg +4.7% vs avg$250
50mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 23h ago
$5.40/mg +13.1% vs avg$54.00
10mg
- 🇺🇸 Hydro Research Peptides91
via Disclosed Labs · 23h ago
$3.50/mg -26.7% vs avg$175
50mg
- 🇺🇸 Peptide Plugs89
✓ verified at source · 23h ago
$2.60/mg -45.5% vs avg$130
50mg
- Peptide Supply Co.83
via Disclosed Labs · 23h ago
$1.25/mg -73.8% vs avg$625
500mg
- 🇺🇸 Ascension Peptides83
via Disclosed Labs · 23h ago
$6.00/mg +25.7% vs avg$60.00
10mg
- 🇺🇸 OROS Research79
✓ verified at source · 23h ago
$5.00/mg +4.7% vs avg$99.99
20mg
- 🇺🇸 Texpeptide69
✓ verified at source · 23h ago
$5.50/mg +15.2% vs avg$55.00
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch SS-31
Get one email when the market actually moves — no newsletter, no noise.
About SS-31
CAS
736992-21-5
Molecular formula
C32H49N9O5
Sequence
D-Arg-Dmt-Lys-Phe-NH2
Typical dose range
40 mg/day subcutaneous (clinical); research range 0.1–2 mg/kg/day subcutaneous
Half-life
~4 hours (subcutaneous)
COAs for SS-31
117 third-party tests across 21 vendors. Each card links to the full report.
For
SS-31
by Ion Peptide· batch 2510-06242026
For
SS-31
by Ion Peptide· batch 2S10-06242026
For
SS-31
by Reta One Labs· batch SS100626
For
S-31
by Ion Peptide· batch SS3150-05042026
For
S-31
by Ion Peptide· batch SS3150-05042026
For
SS-31
by Ion Peptide· batch 2S10-05042026
For
S-31
by Ion Peptide· batch 2S10-05042026
For
SS-31
by Peptidegurus· batch cmojgr89m002r9grxu1x2sttx
For
SS-31
by Peptide Plugs· batch 121-A-D
For
SS-31
by Peptide Partners· batch SPL-3436
For
§-31
by Ion Peptide· batch §-3110-03242026
For
§-31
by Ion Peptide· batch §-3150-03232026
For
SS-31
by Forge Performance Co.· batch Blue Top
For
SS-31
by Qihang Peptide· batch 3
For
SS-31
by Glacier Aminos· batch MTP10GA-03
For
SS-31
by Mile High Compounds· batch SS3-010-MH-04
For
SS-31
by Ion Peptide· batch C3150-02272026
For
SS-31
by Orbitrex Peptides· batch MTP100326
For
SS-31
by Qihang Peptide· batch 2
For
SS-31
by Peptide Supply Co.· batch PSCSS3150001
For
SS-31
by Peptide Partners· batch SS202602
For
SS-31
by Peptide Partners· batch SS202602
For
SS-31
by Ion Peptide· batch SS3110-02032026
For
SS-31
by Licensed Peptides· batch LP02202016
14 citations indexed for SS-31
Study · 2026
Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence
Exposure to ionizing radiation, such as from radiation therapy or accidental radiation exposure can have adverse effects on the heart. While radiation injury in the heart may include cardiomyocyte senescence, there are no available strategies to prevent this phenomenon.
in-vitro · 2026
Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence
Doxorubicin (DOX), an effective chemotherapeutic agent for many types of cancer, is known for significant cardiotoxic side effects, which largely limit its clinical usage.
animal · 2026
Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model
Background Exercise intolerance, promoted by skeletal muscle- and mitochondrial dysfunction, has been identified as a therapeutic target in heart failure with preserved ejection fraction (HFpEF).
Study · 2026
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
Membrane binding and aggregation properties of α-synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy.
animal · 2026
Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice
Ischemic stroke is a severe cerebrovascular disorder characterized by a cascade of pathological processes, including neuroinflammation and apoptosis. These processes lead to high mortality rates and long-term disabilities, imposing substantial socioeconomic burdens.
animal · 2026
Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury
Spinal cord injury (SCI) induces secondary damage characterized by mitochondrial dysfunction, oxidative stress, and apoptosis, which collectively impede neurological recovery. Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects.